What Is the First-Line Treatment for Blastic Plasmacytoid Dendritic Cell Neoplasm?
BPDCN is a hematologic malignancy that can affect the blood, bone marrow, lymph nodes, spleen, liver, and skin. First-line therapy requires structured pre-treatment assessment, as specific eligibility criteria must be confirmed before initiating the preferred approach.
Treatment Approach
First-line management centres on a targeted intravenous therapy administered in defined multi-day cycles — subject to specific pre-treatment eligibility requirements — or intensive chemotherapy-based regimens, with CNS prophylaxis as an essential component; the complete selection criteria and sequencing are in the full protocol.
Clinical Response Goals
- Normalization of peripheral blood counts
- Bone marrow blasts below 5%
- Regression of nodal, spleen, and liver masses
- 100% clearance of all skin lesions with no new lesions
Median time to response: approximately 39 days.
References
DOI: 10.6004/jnccn.2023.7026
- Treatment is continued until disease progression or unacceptable toxicity.
- Hypoalbuminemia is the most consistent predictor of CLS, and hence before initiation of therapy, a serum albumin level of ≥3.2 g/dL with adequate cardiac function is required.
- Based on retrospective studies, ALL-based regimens have resulted in better response rates compared with AML-based or CHOP-based regimens.
- CNS prophylaxis is essential for patients who receive conventional intensive chemotherapy.
- In this trial, Pemmaraju et al first described in detail the clinical response criteria for BPDCN: normalization of peripheral blood counts; bone marrow blasts (<5%); regression of nodal, spleen, and liver masses; and 100% clearance of all skin lesions with no new lesions.
- At a median follow-up of 34 months, the median time to response was 39 days and median duration of response was 24.9 months.